A trial just published in Cell Metabolism puts a number on something cold exposure researchers have suspected for years: raising your metabolic rate and activating brown adipose tissue (BAT) are not the same thing, even when they look identical on a calorimeter readout. A team at the University of Basel infused twelve healthy volunteers with fenoterol, a drug that selectively switches on the beta2-adrenergic receptor, and compared it head-to-head against two hours of real cold exposure. Both raised energy expenditure by a similar amount. Only one of them lit up brown fat. The gap between those two results is the whole point of the paper, and it settles a question that has been sitting in the BAT literature for close to a decade.
Why beta2 receptors looked like the missing piece
In rodents, cold-induced BAT activation runs almost entirely through the beta3-adrenergic receptor: norepinephrine from the sympathetic nervous system binds beta3-AR, triggers the cAMP cascade, and brown fat starts burning fuel to make heat. Translating that into humans turned out to be harder than expected. The beta3-selective drug mirabegron does raise resting energy expenditure and did get picked up as a repurposed obesity drug candidate, but its effect on BAT itself, measured by glucose uptake on PET scans, has always been modest next to what a cold room does. It also pushes up heart rate and blood pressure, which is an awkward side-effect profile for anything aimed at metabolic disease.
That mismatch sent researchers looking at the beta2-adrenergic receptor instead. Human BAT biopsies and cultured brown adipocytes showed more beta2-AR mRNA than beta3-AR, and in vitro work with formoterol, a beta2-selective compound, got uncoupled respiration going in dishes of human brown fat cells when mirabegron couldn’t. Add in genetic data linking certain ADRB2 variants to BAT activity, and beta2-AR looked like a strong candidate for the receptor humans actually rely on.
Putting the theory to the test
The Basel group set up a cleaner test than anything done so far: the same twelve people, screened in advance for a reliable cold-induced thermogenic response, went through both a two-hour mild cold exposure and a two-hour intravenous fenoterol infusion, in randomized order, with a PET-CT scan of the supraclavicular BAT depot after each.
The two interventions behaved differently in almost every way except the topline energy expenditure number. Fenoterol raised EE within minutes and shifted metabolism toward carbohydrate oxidation; cold built up gradually as vasoconstriction gave way to non-shivering thermogenesis, and left fat oxidation essentially unchanged. Cardiovascularly, cold nudged blood pressure up with a steady heart rate, which is the classic sympathetic cold response; fenoterol pushed heart rate up and diastolic pressure down, the textbook beta2 signature. Fenoterol also drove a sharp rise in blood glucose, insulin, and free fatty acids that cold never produced.
The scan told a different story than the calorimeter
None of that would matter much if both interventions had switched brown fat on. They didn’t. Skin temperature over the supraclavicular BAT depot, a proxy for local heat production, rose immediately with cold and stayed flat with fenoterol, even as the drug warmed the skin everywhere else through peripheral vasodilation. The PET scans confirmed it directly: cold exposure produced roughly thirty times more glucose uptake into the BAT depot than fenoterol did, with a correspondingly much larger volume of tissue crossing the activity threshold.
The tissue-level data backed this up. Across two independent RNA-sequencing datasets, the gene for beta3-AR, not beta2-AR, tracked with UCP1 expression, the protein that actually gives brown fat its thermogenic uncoupling ability. Beta2-AR expression, notably, turned out to be no higher in brown fat than in ordinary white fat. In situ staining did find some UCP1-positive cells expressing both receptors side by side, which is a reminder that human BAT is not a uniform tissue, but the functional read-out was unambiguous: beta2-AR signaling on its own isn’t enough to fire up the thermogenic program.
If it’s not brown fat, where do the calories go
That leaves an open question the authors are candid about: fenoterol reliably raises energy expenditure, sometimes more than cold does, so that heat has to be coming from somewhere. The likeliest candidates are skeletal muscle, where beta2 stimulation is already known to raise oxygen consumption and glucose uptake, and futile substrate cycling, where fat is broken down and immediately rebuilt, burning energy without producing useful work. The sharp rise in circulating fatty acids and glycerol during the fenoterol infusion is consistent with exactly that kind of lipolysis-driven cycling. A similar independent trial using salbutamol, another beta2 drug, reached the same conclusion through a different design, which strengthens the case that this isn’t a quirk of one compound.
What this means for how cold exposure fits in
The practical takeaway is a reminder of how specific cold’s effect on the body actually is. A systemic adrenergic signal, delivered pharmacologically, can produce a calorie-burn number that looks just as impressive as a cold room, and yet completely miss the tissue that gives cold exposure its metabolic reputation in the first place. Brown fat activation isn’t a side effect of “feeling warmer” or “heart rate going up.” It’s a specific, receptor-level response that, at least in this trial, only the real cold stimulus reliably triggered.
It’s a useful data point for a debate Wim Hof has been having with skeptics for over two decades: that cold exposure isn’t just a roundabout way of raising your heart rate or your metabolism, but a distinct physiological event that the body doesn’t produce through any other route. Whatever ends up explaining brown fat’s role in long-term metabolic health, it looks like there’s no adrenergic shortcut around actually getting cold.